Does PT-141 work for men?

This site's PT-141 citations do not measure efficacy in men. The two RECONNECT trials that support the approval enrolled 1,267 premenopausal women with hypoactive sexual desire disorder over 24 weeks, and desire scores rose by 0.35 on the integrated FSFI desire scale versus placebo, with nausea, flushing, and headache each in 10% or more. The 52-week extension in 684 women was open-label safety. The US legal-status field is FDA approved, prescription only, as Vyleesi for that one female indication. Use in men is off label or a research-chemical vial, which is not the trial product. A related molecule, melanotan II, produced erections in 8 of 10 men in a 1998 crossover study; that is not a PT-141 result. This FAQ does not invent a male response rate.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of further names and published absences. Leftover harvested questions after the first two absence sets: more brand versus molecule names, side effects the citations did not count, compounding formulas this catalogue does not hold, national FDA and Australia fields, trial windows rather than an onset clock, named combinations with no interaction table, and oral routes that have not been studied.